(CRIS) Curis, Inc. Business Model Canvas Research

Curis, Inc. uses contract research organizations and contract manufacturing organizations to run trials, manage site ops, and prepare clinical supply, which is standard for a clinical-stage biotech. This setup keeps Curis from building a heavy in-house team and shifts fixed cost into flexible service spend.

• Runs studies through CROs
• Sources clinical material via CMOs
• Limits internal infrastructure needs

Curis, Inc. works with academic and translational cancer centers to run biomarker studies and get early clinical readouts in precision oncology, which helps sharpen patient selection in Phase 1/2 trials. These sites also add credibility with investigators and regulators, especially when data comes from tumor-specific, biomarker-driven cohorts.

• Supports biomarker validation
• Improves patient selection
• Builds investigator trust
• Strengthens regulatory confidence

Curis, Inc. uses regulatory and IND-enabling work to move compounds from preclinical testing to human studies. In the U.S., an IND usually faces a 30-day FDA review window, so Curis must package safety data, CMC files, and nonclinical results fast and cleanly.

These steps de-risk first-in-human testing and keep programs on track for 2026 development gates; Curis spent $18.7 million on R&D in 2024, showing how much of its budget is tied to this stage.

• Build IND-ready safety packages
• Manage FDA and agency feedback
• Support first human dosing

Curis, Inc. runs partnered commercialization by tracking Erivedge and other collaboration duties, lining up supply, milestone checks, and royalty billing. It is a recurring operating task tied to partnered revenue, with Erivedge still a core royalty asset for the Company.

• Tracks partner milestones

• Coordinates supply and delivery

• Administers royalties and receipts

Curis, Inc. depends on patents, licenses, and contract rights to protect its pipeline and share in partner economics; in biotech, that IP is often the main asset, since one patent family can define value for years. Strong collaboration rights also shape milestone and royalty cash flows, which matter more than physical assets in this model.

• Patents defend pipeline exclusivity
• Licenses support partnered programs
• Contract rights drive partner economics

Curis, Inc. is headquartered in Lexington, Massachusetts, and its scientific and management team is a core asset for discovery, development, and partner talks. For a clinical-stage biotech, internal know-how matters most because it drives program design, trial decisions, and deal execution.

• Headquarters: Lexington, Massachusetts
• Core resource: scientific team
• Core resource: management team
• Supports discovery, development, partnering

Erivedge gives Curis, Inc. a real commercial proof point: Roche and Genentech turned Curis science into an approved, marketed oncology drug, and Erivedge has been sold since 2012. That partner-backed launch strengthens outside confidence in Curis, Inc.'s drug discovery platform and lowers perceived execution risk.

• Marketed asset: Erivedge
• Partner validation: Roche and Genentech
• Approval year: 2012

Curis, Inc.'s multi-asset cancer pipeline gives investors multiple shots on goal: if one program slips, another can still drive value. The mix of clinical and preclinical candidates also spreads scientific and FDA risk across more than one mechanism, which is important for a small biotech with limited cash and high trial failure rates.

• Multiple programs, not one bet
• Spreads clinical and regulatory risk
• Supports partnering and licensing upside

Curis, Inc. uses investor relations to keep capital-market support while it advances a small, high-risk pipeline. Regular quarterly updates help explain clinical progress, partnership value, and cash needs, and that transparency matters when a development-stage biotech depends on external funding.

• Show pipeline milestones clearly
• Explain cash runway and funding risk
• Build trust with steady disclosure

Curis, Inc. uses medical community education by sharing clinical and scientific data at publications and meetings, which helps oncologists and researchers track its pipeline and understand the evidence base. As a clinical-stage oncology Company with no approved products, this is a low-cost way to build awareness now and support future uptake if any asset wins approval.

• Publishes data to reach specialists
• Uses meetings to build credibility
• Supports future adoption after approval

Curis, Inc. uses company announcements, SEC filings, and investor materials to share pipeline milestones and collaboration updates, keeping its oncology story visible to the market. For a public biotech, this channel matters because investors track clinical progress, partnership news, and cash runway from each release.

• Pipeline milestones
• Collaboration updates
• Public investor visibility

Curis, Inc. relies on medical and regulatory networks to move specialty oncology programs from lab work into review and use, working with physicians, researchers, and regulators at each step. These channels shape trial design, data review, and approval readiness, which is critical in a market where oncology drugs face stricter evidence and safety checks than many other therapies.

• Physicians guide clinical use.
• Researchers support trial design.
• Regulators drive approval path.

Oncologists and cancer treatment centers are Curis, Inc.'s main buyers and trial gatekeepers. They shape prescribing and study enrollment, and with about 2.0 million new U.S. cancer cases expected in 2024, they need clear proof of benefit before adopting a new oncology asset.

• Drive prescribing and trial enrollment
• Require strong phase 2/3 evidence
• Decide at the point of care

Curis, Inc. targets biopharma partners and licensees that can fund development or commercialize its oncology assets. This is a B2B segment built around collaboration, where other drug companies seek access to Curis’s cancer programs, including licensing and shared-risk deal structures.

• Strategic partners fund or commercialize assets
• Focuses on oncology innovation access
• Collaboration drives B2B demand

Curis, Inc.'s general and administrative overhead covers corporate staff, finance, SEC reporting, investor relations, and headquarters costs; for a small public biotech, these fixed expenses keep running even when pipeline spend changes. Public-company admin is a recurring cash drain, so this line stays material in every filing.

• Corporate staff and finance
• SEC reporting and IR
• Headquarters overhead
• Recurring public-company cost

Curis, Inc. keeps manufacturing and quality ops asset-light: CMC spend sits in clinical supplies, formulation, packaging, and quality systems, while outsourced manufacturing stays a material cash cost. For a clinical-stage model, these costs sit inside R&D and can swing with trial cadence.

• CMC covers formulation and packaging
• Quality systems need ongoing spend
• Outsourced manufacturing remains material

Curis, Inc. can turn pipeline assets into near-term cash by using license and option fees, a common biotech deal structure that brings upfront payments before any drug reaches market. This matters because Curis still depends on external funding, so non-dilutive deal cash can help bridge R&D spend while partners pay to reserve or license programs.

• Upfront fees create immediate cash.
• Options monetize pipeline risk early.
• Licenses convert asset value into cash.

Curis, Inc. has no approved product revenue today, so future commercialization proceeds are still an option value stream, not a current cash driver. If its pipeline reaches approval and gains market access, product sales could create later-stage economics, but this remains contingent on clinical success, pricing, and reimbursement.

• Current revenue: no product sales
• Upside depends on approval
• Market access drives monetization